Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction
Status:
Completed
Trial end date:
2018-02-27
Target enrollment:
Participant gender:
Summary
Pilot study to evaluate the activity of omalizumab in the prevention of recurrent oxaliplatin
hypersensitivity reaction (HSR) in oxaliplatin-sensitive patients. The study will also
evaluate the safety of omalizumab (Xolair) when administered in this setting.